Navigation Links
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
Date:3/1/2010

pany specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of primary and metastatic liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer agents to the liver while controlling the systemic exposure of those agents.  In addition to its fully enrolled Phase III metastatic melanoma study, the Company is currently conducting trials to treat other forms of tumor metastases to the liver. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
2. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
3. Delcath Enters Agreement to Sell 869,565 Units
4. Delcath Systems Granted Third Orphan Drug Designation
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
7. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
8. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
9. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
10. New Online Tutorials for NCBI resources BioSystems and DCODE
11. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Working in collaboration with the National Amyloidosis ... , Richmond Pharmacology is the first centre worldwide to ... an investigational RNAi therapeutic being developed for the treatment of ... heart. Read press release ... St Georges University of London , Richmond ...
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... N.J., March 26, 2015  Roka Bioscience, Inc. ... focused on providing advanced testing solutions for the ... results for the three months and full year ... 2014 Financial Results:Revenue for the quarter ended December ... for the fourth quarter of 2013 and $1.5 ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - SQI Diagnostics ... announced that after dealing with certain matters, including the ... shareholders held on March 26, 2015 (the "Meeting") was ... April 8, 2015 at 11:00 a.m. ( Toronto ... has been changed from that previous disclosed. The Meeting ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... Now Has Four Phase 2 Trials Underway, MONTVALE, ... ) has dosed the first patient in a 160-patient ... failure. BREAK (Beginning a,Randomized Evaluation of the A.G.E. [Advanced ... a randomized,double-blind, placebo controlled study to assess the effect ...
... NEW YORK, May 13 NeoStem, Inc. (Amex: ... and long-term,storage of adult stem cells for future medical ... a new stem cell collection center in Coral,Gables, Florida, ... NeoStem,s Chairman and Chief Executive Officer,commented: "Securing the Florida ...
... 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today ... 2 study of subcutaneously,administered LHRH antagonist cetrorelix ... has been accepted for publication in an,upcoming ...
Cached Biology Technology:Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 2AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 4AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 5AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 6
(Date:3/17/2015)... DIEGO , March 17, 2015 ... emotion analytics software, today announced general availability of ... web service for the analysis of facial expressions. ... experience advertising, media content, products and services. It ... attention, engagement and sentiment - as derived from ...
(Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
(Date:3/10/2015)... , March 10, 2015 ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured ... the past two years. Specifically, "Personalized Medicine ... downloaded scientific papers published in 2013 and 2014 from ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... Tobacco smoking by pregnant women has long been ... adverse effects on the development of a fetus. ... outcomes, including low birth weight, sudden infant death syndrome, ... and nicotine use in offspring. Despite this extensive literature, ...
... to help fertilize crops, it is vital to understand the ... Burkholderia , for example, includes dangerous disease-causing pathogens one ... but also many species that are safe and important ... good and evil be told apart? Yes, UCLA life scientists ...
... - Scientists at A*STAR,s Institute of Molecular and Cell ... sequenced and analysed the genome of the elephant shark. ... human and other vertebrate genomes revealed why the skeleton ... The findings carry potential implications for human bone disease ...
Cached Biology News:Maternal stress hormones and maternal smoking increase daughter's risk of nicotine dependence 2UCLA life scientists, colleagues differentiate microbial good and evil 2UCLA life scientists, colleagues differentiate microbial good and evil 3Elephant shark genome provides new insights into bone formation and adaptive immunity in humans 2Elephant shark genome provides new insights into bone formation and adaptive immunity in humans 3
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Jak3 Antibody Ship: Hot Store: -20 C...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: